Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BHVN Biohaven Pharmaceutical Holding Co Ltd.

Trading 12-11 14:49:55 EST

11.42

+0.82

+7.73%

High11.71	Low10.65	Vol2.30M
Open10.79	D1 Closing10.60	Amplitude10.05%
Mkt Cap1.51B	Tradable Cap1.28B	Total Shares132.64M
T/O26.13M	T/O Rate2.05%	Tradable Shares112.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BHVN","market":"US","secType":"STK","nameCN":"Biohaven Pharmaceutical Holding Co Ltd.","latestPrice":11.4199,"timestamp":1765482585900,"preClose":10.6,"halted":0,"volume":2299004,"delay":0,"floatShares":112000000,"shares":132637000,"eps":-7.586766,"marketStatus":"Trading","change":0.8199,"latestTime":"12-11 14:49:55 EST","open":10.79,"high":11.7099,"low":10.645,"amount":26129134.546660002,"amplitude":0.100462,"askPrice":11.45,"askSize":116,"bidPrice":11.4,"bidSize":119,"shortable":3,"etf":0,"ttmEps":-7.586766,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1493870400000,"exchange":"NYSE","adjPreClose":10.6,"preHourTrading":{"tag":"盘前","latestPrice":10.58,"preClose":10.6,"latestTime":"09:29 EST","volume":4386,"amount":46416.037992,"timestamp":1765463376092},"postHourTrading":{"tag":"盘后","latestPrice":10.628,"preClose":10.6,"latestTime":"19:20 EST","volume":82216,"amount":871595.4278,"timestamp":1765412415160},"volumeRatio":0.847615,"optionData":{"bulkOrders":[{"symbol":"BHVN","call":true,"expireDate":1766120400000,"strike":"12.5","timestamp":1765465566677,"price":0.63,"volume":3200,"amount":201600,"type":"+"},{"symbol":"BHVN","call":true,"expireDate":1766120400000,"strike":"10.0","timestamp":1765465566674,"price":1.5,"volume":1350,"amount":202500,"type":"-"}]},"impliedVol":1.4266,"impliedVolPercentile":0.832},"requestUrl":"/m/hq/s/BHVN","defaultTab":"news","newsList":[{"id":"2590102445","title":"BUZZ-Biohaven jumps as cancer treatment shows promise in early-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590102445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590102445?lang=en_us&edition=fundamental","pubTime":"2025-12-12 00:31","pubTimestamp":1765470697,"startTime":"0","endTime":"0","summary":"BUZZ-Biohaven jumps as cancer treatment shows promise in early-stage trial** Shares of drugmaker Biohaven BHVN.N rise 8.5% to $11.50 ** Co says its experimental therapy, BHV-1510, in combination with Regeneron Pharmaceuticals' REGN.O Libtayo, showed efficacy and manageable safety across several tumors in an early-stage trial** Co says patients receiving the treatment every three weeks showed a 72.7% confirmed response** The combination therapy is being tested among pre-treated patients with advanced cancers - BHVN** RBC Capital Markets says it \"sees these efficacy and safety results as promising\"** Including session moves, stock down 69.2% YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL4N3XH18A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","BK4585","LU2362541273.HKD","BK4588","LU1093756168.USD","LU0109394709.USD","BK4139","LU0823434583.USD","LU0823434740.USD","LU0114720955.EUR","LU0289739699.SGD","BHVN","LU2237438978.USD","LU0053666078.USD","LU2468319806.SGD","LU2106854487.HKD","LU0058720904.USD","LU0823416689.USD","LU2023250504.SGD","LU0320765992.SGD","LU0882574055.USD","LU2089984988.USD","LU1093756325.SGD","LU2362541513.USD","LU2362540622.SGD","LU1974910355.USD","LU0889565916.HKD","LU1917777945.USD"],"gpt_icon":0},{"id":"2590292518","title":"Biohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590292518","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590292518?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:02","pubTimestamp":1765454559,"startTime":"0","endTime":"0","summary":"Biohaven Ltd. has announced the presentation of clinical safety and efficacy data for BHV-1510, a next-generation Trop2 antibody drug conjugate , in combination with the anti-PD-1 monoclonal antibody cemiplimab. The results were presented at the 2025 European Society for Medical Oncology  Immuno-Oncology Congress held from December 10-12, 2025, in London, United Kingdom. In a Phase 1 trial involving pretreated patients with advanced or metastatic cancer, including those with prior PD-1 treatment, the combination of BHV-1510 and cemiplimab demonstrated confirmed objective response rates of 60% in non-small cell lung cancer , 100% in endometrial cancer, and 50% in urothelial cancer. The safety profile showed low rates of adverse events attributed to the unconjugated payload, with no cases of interstitial lung disease reported. The poster presentation is available on Biohaven's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL3WQklh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1093756168.USD","BHVN","LU1093756325.SGD"],"gpt_icon":0},{"id":"2588926045","title":"Biohaven Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588926045","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588926045?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:21","pubTimestamp":1764764460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BHVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 07:21 ET (12:21 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4139","LU1093756325.SGD","BHVN"],"gpt_icon":0},{"id":"2588323043","title":"HC Wainwright Downgrades Biohaven to Neutral From Buy, Adjusts Price Target to $11 From $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2588323043","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588323043?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:46","pubTimestamp":1764762367,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) has an average rating of overweight and mean price target of $20.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","LU1093756168.USD","BHVN","BK4139"],"gpt_icon":0},{"id":"2588763741","title":"Biohaven (BHVN): Evaluating Valuation After UBS Downgrade and Shifting Analyst Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2588763741","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588763741?lang=en_us&edition=fundamental","pubTime":"2025-12-01 12:31","pubTimestamp":1764563477,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) is in the spotlight after UBS downgraded its rating and revised its outlook. Other firms have made similar changes as well. These shifts in analyst sentiment can impact investor confidence and trading activity.\nSee our latest analysis for Biohaven.\nBiohaven’s share price has seen sharp swings lately, rising 5.8% in a single day but still down more than 41% for the month and over 73% year-to-date. Despite some lively trading sessions and high-profile analyst downgrades, the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-evaluating-valuation-after-ubs-downgrade-and-s","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-evaluating-valuation-after-ubs-downgrade-and-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BHVN"],"gpt_icon":0},{"id":"2586478263","title":"Biohaven Cut to Neutral From Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478263","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586478263?lang=en_us&edition=fundamental","pubTime":"2025-11-26 22:51","pubTimestamp":1764168660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BHVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2025 09:51 ET (14:51 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1093756168.USD","BHVN","LU1093756325.SGD"],"gpt_icon":0},{"id":"2586254518","title":"UBS Downgrades Biohaven to Neutral From Buy, $11 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2586254518","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586254518?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:26","pubTimestamp":1764159995,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) has an average rating of overweight and mean price target of $20.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU1093756168.USD","LU1093756325.SGD","BHVN"],"gpt_icon":0},{"id":"2585432178","title":"Assessing Biohaven (BHVN) Valuation Following $175 Million Equity Offering and Underwriter Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2585432178","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585432178?lang=en_us&edition=fundamental","pubTime":"2025-11-24 10:14","pubTimestamp":1763950496,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) has just wrapped up a $175 million follow-on equity offering, drawing in new co-lead underwriters. The move provides fresh capital and invites close attention from investors considering future dilution.\nSee our latest analysis for Biohaven.\nFollowing this capital raise and a series of underwriter changes, Biohaven’s share price has shown sharp volatility, jumping 16.8% over the past week, but still down 41.6% for the month and facing a year-to-date share price return of -74%...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-following-175-million-equi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-following-175-million-equi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4215","BHVN","EQR","LU1093756168.USD","BK4139","LU1093756325.SGD","BK4585","BK4588"],"gpt_icon":0},{"id":"2584189379","title":"U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe's","url":"https://stock-news.laohu8.com/highlight/detail?id=2584189379","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584189379?lang=en_us&edition=fundamental","pubTime":"2025-11-20 16:25","pubTimestamp":1763627108,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe'sNov 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agios P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nL4N3WW0LU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LOW","MDGL","JACK","DY","ROP","AGIO","LU1548497426.USD","SG9999015952.SGD","IE0002141913.USD","NVDD","NVDY","PTGX","WSM","BHVN","TJX","SNVD.UK","NVDU","AVAV","LU1868836591.USD","NVDS","ACM","IONQ","NVD3.UK","RRC","NVDX","2NVD.UK","LU1868837136.USD","NVIW.SI","PANW","VVV","NVDA","TGT","NVD","AIZ","GLOB","NVDL","KGC","LU2279689827.SGD","ENTG","SEMR","NVDS.UK","RVMD","UNH","OPK","LU2756315664.SGD","LU1169589451.USD","NVD2.UK","Q","3NVD.UK","LU0170899867.USD"],"gpt_icon":0},{"id":"2584921296","title":"Biohaven Announces Proposed Public Offering Of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584921296","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584921296?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:20","pubTimestamp":1763572845,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - Biohaven Ltd ::*BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES*BIOHAVEN LTD: COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF ITS COMMON SHARES  ((Reuters ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDbrfzhY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BHVN","BK4139","LU1093756168.USD"],"gpt_icon":0},{"id":"2584957018","title":"Biohaven Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2584957018","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584957018?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:26","pubTimestamp":1763490360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BHVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 13:26 ET (18:26 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4139","BHVN","LU1093756168.USD"],"gpt_icon":0},{"id":"2584959394","title":"Biohaven call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2584959394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584959394?lang=en_us&edition=fundamental","pubTime":"2025-11-18 23:05","pubTimestamp":1763478313,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Biohaven (BHVN) with 1,855 calls trading, 1.3x expected, and implied vol increasing over 5 points to 122.30%. Dec-2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756325.SGD","BK4139","BHVN","LU1093756168.USD"],"gpt_icon":0},{"id":"2584934870","title":"Biohaven Price Target Maintained With a $16.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2584934870","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584934870?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:56","pubTimestamp":1763466960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BHVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 06:56 ET (11:56 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BHVN","LU1093756325.SGD","BK4139"],"gpt_icon":0},{"id":"1161374580","title":"Stock Track | Biohaven Pharmaceutical Soars 5.18% Pre-market as CEO Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1161374580","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161374580?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:30","pubTimestamp":1763386228,"startTime":"0","endTime":"0","summary":"Biohaven Pharmaceutical Holding Co Ltd. (BHVN) stock is experiencing a significant pre-market surge on Monday, with shares climbing 5.18% ahead of the regular trading session. This notable uptick has...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BHVN"],"gpt_icon":0},{"id":"2584623862","title":"Biohaven CEO Vlad Coric Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584623862","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584623862?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:32","pubTimestamp":1763382740,"startTime":"0","endTime":"0","summary":"Vlad Coric, Chief Executive Officer of Biohaven Ltd., reported the acquisition of common shares of Biohaven Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL7vx9jX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Biohaven CEO Vlad Coric Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","LU1093756325.SGD","BK4139","BHVN"],"gpt_icon":0},{"id":"2583892665","title":"A Look at Biohaven’s Valuation Following $175 Million Share Offering and Recent FDA Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2583892665","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583892665?lang=en_us&edition=fundamental","pubTime":"2025-11-16 11:29","pubTimestamp":1763263761,"startTime":"0","endTime":"0","summary":"Biohaven (NYSE:BHVN) just completed a $175 million follow-on public offering, issuing new shares at $7.50, which is lower than its prior trading price. This move is aimed at bolstering the company’s balance sheet after recent challenges.\nSee our latest analysis for Biohaven.\nBiohaven’s recent stock performance has been dominated by sharp moves, most notably a roughly 48% drop in the last three months after the FDA declined to approve its experimental drug. This led to a follow-on stock...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/a-look-at-biohavens-valuation-following-175-million-share-of","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/a-look-at-biohavens-valuation-following-175-million-share-of","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1093756325.SGD","LU1093756168.USD","BK4139","BHVN"],"gpt_icon":0},{"id":"2583030680","title":"H.C. Wainwright Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583030680","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583030680?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:39","pubTimestamp":1763163543,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Biohaven Ltd., with a price target of $30.00. According to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-biohaven-ltd-bhvn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-biohaven-ltd-bhvn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BHVN"],"gpt_icon":0},{"id":"2583177516","title":"Biohaven Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2583177516","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583177516?lang=en_us&edition=fundamental","pubTime":"2025-11-14 03:52","pubTimestamp":1763063520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BHVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 14:52 ET (19:52 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1093756168.USD","LU1093756325.SGD","BHVN"],"gpt_icon":0},{"id":"2582303647","title":"BUZZ-U.S. STOCKS ON THE MOVE-Floor & Decor, Starbucks, gold miners","url":"https://stock-news.laohu8.com/highlight/detail?id=2582303647","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582303647?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:56","pubTimestamp":1762962963,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Floor & Decor, Starbucks, gold minersEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslett","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL6N3WO0T2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VG","YTRA","LB","AMD","BROS","FLNG","LEGN","LU0788109394.HKD","SBUX","FTCI","LU0823421333.USD","VVX","LU2471134879.HKD","LU0096364046.USD","T","LU0882574055.USD","ARCO","LU0278409577.USD","BKR","BBWI","LU0795875086.SGD","CWAN","CRWS","KGS","BHVN","ARTV","CRMD","NEM","LWAY","COGT","LU0823421416.USD","XOM","IBM","ALKS","LU1223082196.USD","LU2471134523.USD","CREX","LU0208291251.USD","BK4179","LU2552382132.HKD","MBRX","PBF","LCID","VLN","FND","CVX","BHF"],"gpt_icon":1},{"id":"2582727653","title":"BUZZ-U.S. STOCKS ON THE MOVE-ExxonMobil, Yatra, Venture Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2582727653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582727653?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:13","pubTimestamp":1762956792,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-ExxonMobil, Yatra, Venture GlobalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL6N3WO0IC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KGS","LU0096364046.USD","LU2458330243.SGD","IBM","LU0300736492.USD","ARCO","LU0795875086.SGD","LU0823434740.USD","LU2471134523.USD","VLN","LCID","LU0278409577.USD","CWAN","VVX","BBWI","LU2552382132.HKD","LU2750360997.AUD","LU0882574055.USD","ARTV","SG9999015945.SGD","BHVN","LU2750360641.GBP","VG","ALKS","FTCI","LU2471134879.HKD","CREX","FLNG","LU0109394709.USD","LU1883866441.USD","LU0788109394.HKD","CRMD","COGT","CRWS","LU0109392836.USD","YTRA","LU0456854461.SGD","MBRX","XOM","LU0321505868.SGD","LU0823421416.USD","LU0943347566.SGD","LU2471134796.USD","LU0823421333.USD","LU0823434583.USD","LU0354030511.USD","LU2458330169.SGD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.biohaven.com","stockEarnings":[{"period":"1week","weight":0.1623},{"period":"1month","weight":0.3607},{"period":"3month","weight":-0.2466},{"period":"6month","weight":-0.3144},{"period":"1year","weight":-0.7511},{"period":"ytd","weight":-0.7162}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.074852},{"month":2,"riseRate":0.25,"avgChangeRate":-0.026088},{"month":3,"riseRate":0.25,"avgChangeRate":-0.102404},{"month":4,"riseRate":0.5,"avgChangeRate":0.0146},{"month":5,"riseRate":0.625,"avgChangeRate":0.144142},{"month":6,"riseRate":0.555556,"avgChangeRate":0.056007},{"month":7,"riseRate":0.555556,"avgChangeRate":0.010799},{"month":8,"riseRate":0.666667,"avgChangeRate":0.043364},{"month":9,"riseRate":0.777778,"avgChangeRate":0.09598},{"month":10,"riseRate":0.555556,"avgChangeRate":-0.072057},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.042561},{"month":12,"riseRate":0.555556,"avgChangeRate":0.04734}],"exchange":"NYSE","name":"Biohaven Pharmaceutical Holding Co Ltd.","nameEN":"Biohaven Pharmaceutical Holding Co Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biohaven Pharmaceutical Holding Co Ltd.,BHVN,Biohaven Pharmaceutical Holding Co Ltd.股票,Biohaven Pharmaceutical Holding Co Ltd.股票老虎,Biohaven Pharmaceutical Holding Co Ltd.股票老虎国际,Biohaven Pharmaceutical Holding Co Ltd.行情,Biohaven Pharmaceutical Holding Co Ltd.股票行情,Biohaven Pharmaceutical Holding Co Ltd.股价,Biohaven Pharmaceutical Holding Co Ltd.股市,Biohaven Pharmaceutical Holding Co Ltd.股票价格,Biohaven Pharmaceutical Holding Co Ltd.股票交易,Biohaven Pharmaceutical Holding Co Ltd.股票购买,Biohaven Pharmaceutical Holding Co Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}